Cardiology Research Institute, Tomsk National Research Medical Center
| Autor: | E. V. Grakova, K. V. Kopyeva, A. T. Teplyakov, L. K. Isakov, M. N. Sinkova, N. I. Tarasov |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Российский кардиологический журнал, Vol 27, Iss 7 (2022) |
| Druh dokumentu: | article |
| ISSN: | 1560-4071 2618-7620 |
| DOI: | 10.15829/1560-4071-2022-4753 |
| Popis: | Aim. To assess the prognostic role of cardiac biomarkers (galectin-3, soluble ST2 (sST2), and N-terminal pro-brain natriuretic peptide (NT-proBNP)) in risk stratification of adverse cardiovascular events (CVEs) in patients with heart failure (HF) after implantation of an automatic implantable cardioverter-defibrillator (AICD) within 12-month follow-up period.Material and methods. The study included 57 patients (men, 41; mean age, 65 (59; 68) years) with coronary artery disease and NYHA class II-III HF with left ventricular ejection fraction of 34 [26; 40]%. All patients were implanted with AICD. Serum levels of NT-proBNP, sST2, and galectin-3 were determined by enzyme immunoassay prior to AICD implantation.Results. It has been established that in order to stratify the risk of unfavorable HF in patients after AICD implantation for 12-month follow-up, all three studied biomarkers can be considered as prognostic factors. Thus, an increase in the level of NT-proBNP ≥1046,6 pg/ml (AUC=0,68; p=0,009), sST2 ≥34,43 ng/ml (AUC=0,78; p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|